Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2020

View Archived Issues

T-cell aging induces broad senescence

ALK is a candidate thinness gene

In vivo data support human trials of CRISPR/Cas9-mediated homology-directed repair treatment for SCD

ExoFlo stem cell-derived exosomes show promise for severe COVID-19 disease

FDA grants approval to artesunate for injection in severe malaria

Gilead identifies new MAP4K1 inhibitors

TGF-beta receptor type-1 inhibitors discovered at Medshine Discovery

Dana-Farber Cancer Institute patents EP300 degraders

Merck & Co. identifies new Nav1.8 channel blockers

ViiV Healthcare presents HIV-1 capsid protein p24 assembly inhibitors

Researchers unveil PAR-1 as being involved in ALS pathogenesis

gnomAD identifies rare loss-of-function variants

FDA approves VESIcare LS oral suspension for neurogenic detrusor overactivity in pediatric patients

FDA clears Expression Therapeutics' IND for phase I trial of gene therapy for hemophilia A

Zeposia receives European approval for the treatment of adult patients with RRMS

Positive topline data from phase II BRIGHT trial of Zygel in autism spectrum disorder

Positive results from compassionate use study of Organicell Flow in severe COVID-19

First-in-human data for B-VEC in patients with recessive dystrophic epidermolysis bullosa

Corin overcomes BRAF inhibitor resistance in vivo

DMC clears clinical study of TJM-2 in severe COVID-19 to advance into part 2

FDA clears initiation of phase II study of PB-1046 for hospitalized patients with COVID-19

New phase III trial to evaluate Actemra with remdesivir for severe COVID-19 pneumonia

Atriva plans to study ATR-002 in phase II trial for COVID-19

New arm of I-SPY COVID trial to evaluate razuprotafib for COVID-19-related ARDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...